Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).

Details

Language :

English

ISSN :

0732183X

Volume :

41

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

164018096

Full Text :

https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1111